TipRanks
Intellia Therapeutics (GB:0JBU)
LSE:0JBU
UK Market
0JBU
Intellia Therapeutics
RESEARCH TOOLSreports

Intellia Therapeutics (0JBU) Share Forecast & Price Target

7 Followers
See the Price Targets and Ratings of:

0JBU Analyst Ratings

Moderate Buy
13Ratings
Moderate Buy
6 Buy
5 Hold
2 Sell
Based on 13 analysts giving stock ratings to
Intellia
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0JBU Stock 12 Month Forecast

Average Price Target

$19.91
▲(52.33% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $19.91 with a high forecast of $49.00 and a low forecast of $8.00. The average price target represents a 52.33% change from the last price of $13.07.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","50":"$50","17.75":"$17.75","28.5":"$28.5","39.25":"$39.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":49,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$49.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.90909090909091,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,17.75,28.5,39.25,50],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.4,15.215384615384616,18.03076923076923,20.846153846153847,23.661538461538463,26.47692307692308,29.292307692307695,32.10769230769231,34.92307692307693,37.73846153846154,40.55384615384616,43.369230769230775,46.184615384615384,{"y":49,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.4,12.977622377622378,13.555244755244756,14.132867132867133,14.710489510489511,15.288111888111889,15.865734265734266,16.443356643356644,17.02097902097902,17.5986013986014,18.17622377622378,18.753846153846155,19.33146853146853,{"y":19.90909090909091,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.4,12.061538461538461,11.723076923076924,11.384615384615385,11.046153846153846,10.707692307692309,10.36923076923077,10.03076923076923,9.692307692307693,9.353846153846154,9.015384615384615,8.676923076923078,8.338461538461539,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.378,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.811,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.748,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.101,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.26,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.118,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.31,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.205,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.08,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.719,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.67,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.4,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$49.00Average Price Target$19.91Lowest Price Target$8.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on GB:0JBU
Derek Archila
Wells Fargo
Wells Fargo
$15
Hold
14.77%
Upside
Reiterated
10/15/26
Wells Fargo Keeps Their Hold Rating on Intellia Therapeutics (NTLA)
Barclays Analyst forecast on GB:0JBU
Eliana Merle
Barclays
Barclays
$8
Sell
-38.79%
Downside
Initiated
10/07/26
Barclays starts Intellia at Underweight on expected commercial headwindsBarclays starts Intellia at Underweight on expected commercial headwinds
Wedbush Analyst forecast on GB:0JBU
David Nierengarten
Wedbush
Wedbush
$12→$13
Hold
-0.54%
Downside
Reiterated
09/09/26
Intellia Therapeutics price target raised to $13 from $12 at WedbushIntellia Therapeutics price target raised to $13 from $12 at Wedbush
H.C. Wainwright Analyst forecast on GB:0JBU
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$25
Buy
91.28%
Upside
Reiterated
09/09/26
Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (NASDAQ: COLL), Revolution Medicines (NASDAQ: RVMD) and Intellia Therapeutics (NASDAQ: NTLA)
TD Cowen Analyst forecast on GB:0JBU
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
09/04/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Intellia Therapeutics (NASDAQ: NTLA) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
JonesTrading Analyst forecast on GB:0JBU
Debanjana Chatterjee
JonesTrading
JonesTrading
$29
Buy
121.88%
Upside
Reiterated
08/14/26
Intellia Therapeutics: Buy Rating Reiterated as Clinical Progress and Risk Management Support Unchanged $29 Price Target
Morgan Stanley Analyst forecast on GB:0JBU
Terence Flynn
Morgan Stanley
Morgan Stanley
$15
Hold
14.77%
Upside
Assigned
08/10/26
Morgan Stanley Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)
Bank of America Securities Analyst forecast on GB:0JBU
Alec Stranahan
Bank of America Securities
Bank of America Securities
$19→$17
Hold
30.07%
Upside
Reiterated
08/07/26
Bank of America Securities Remains a Hold on Intellia Therapeutics (NTLA)
Evercore ISI Analyst forecast on GB:0JBU
Jonathan Miller
Evercore ISI
Evercore ISI
$16→$24
Buy
83.63%
Upside
Upgraded
08/07/26
Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISIIntellia Therapeutics upgraded to Outperform from In Line at Evercore ISI
William Blair Analyst forecast on GB:0JBU
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA), Haemonetics (NYSE: HAE) and Nuvation Bio (NYSE: NUVB)
Goldman Sachs Analyst forecast on GB:0JBU
Salveen Richter
Goldman Sachs
Goldman Sachs
$9
Sell
-31.14%
Downside
Reiterated
08/06/26
Intellia Therapeutics (NTLA) Receives a Sell from Goldman Sachs
Canaccord Genuity Analyst forecast on GB:0JBU
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$49
Buy
274.90%
Upside
Reiterated
08/06/26
Analyst Maintains Buy on Intellia as Lonvo-z Progress and Strong Cash Runway Support Unchanged $49 Price Target
RBC Capital Analyst forecast on GB:0JBU
Luca Issi
RBC Capital
RBC Capital
$15
Hold
14.77%
Upside
Reiterated
08/06/26
RBC Capital Sticks to Its Hold Rating for Intellia Therapeutics (NTLA)
Wolfe Research Analyst forecast on GB:0JBU
Andy Chen
Wolfe Research
Wolfe Research
$9
Sell
-31.14%
Downside
Downgraded
07/15/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (NYSE: BLCO) and Intellia Therapeutics (NASDAQ: NTLA)
J.P. Morgan Analyst forecast on GB:0JBU
Brian Cheng
J.P. Morgan
J.P. Morgan
$8
Sell
-38.79%
Downside
Reiterated
05/13/26
J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on GB:0JBU
Derek Archila
Wells Fargo
Wells Fargo
$15
Hold
14.77%
Upside
Reiterated
10/15/26
Wells Fargo Keeps Their Hold Rating on Intellia Therapeutics (NTLA)
Barclays Analyst forecast on GB:0JBU
Eliana Merle
Barclays
Barclays
$8
Sell
-38.79%
Downside
Initiated
10/07/26
Barclays starts Intellia at Underweight on expected commercial headwindsBarclays starts Intellia at Underweight on expected commercial headwinds
Wedbush Analyst forecast on GB:0JBU
David Nierengarten
Wedbush
Wedbush
$12→$13
Hold
-0.54%
Downside
Reiterated
09/09/26
Intellia Therapeutics price target raised to $13 from $12 at WedbushIntellia Therapeutics price target raised to $13 from $12 at Wedbush
H.C. Wainwright Analyst forecast on GB:0JBU
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$25
Buy
91.28%
Upside
Reiterated
09/09/26
Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (NASDAQ: COLL), Revolution Medicines (NASDAQ: RVMD) and Intellia Therapeutics (NASDAQ: NTLA)
TD Cowen Analyst forecast on GB:0JBU
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
09/04/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Intellia Therapeutics (NASDAQ: NTLA) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
JonesTrading Analyst forecast on GB:0JBU
Debanjana Chatterjee
JonesTrading
JonesTrading
$29
Buy
121.88%
Upside
Reiterated
08/14/26
Intellia Therapeutics: Buy Rating Reiterated as Clinical Progress and Risk Management Support Unchanged $29 Price Target
Morgan Stanley Analyst forecast on GB:0JBU
Terence Flynn
Morgan Stanley
Morgan Stanley
$15
Hold
14.77%
Upside
Assigned
08/10/26
Morgan Stanley Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)
Bank of America Securities Analyst forecast on GB:0JBU
Alec Stranahan
Bank of America Securities
Bank of America Securities
$19→$17
Hold
30.07%
Upside
Reiterated
08/07/26
Bank of America Securities Remains a Hold on Intellia Therapeutics (NTLA)
Evercore ISI Analyst forecast on GB:0JBU
Jonathan Miller
Evercore ISI
Evercore ISI
$16→$24
Buy
83.63%
Upside
Upgraded
08/07/26
Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISIIntellia Therapeutics upgraded to Outperform from In Line at Evercore ISI
William Blair Analyst forecast on GB:0JBU
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA), Haemonetics (NYSE: HAE) and Nuvation Bio (NYSE: NUVB)
Goldman Sachs Analyst forecast on GB:0JBU
Salveen Richter
Goldman Sachs
Goldman Sachs
$9
Sell
-31.14%
Downside
Reiterated
08/06/26
Intellia Therapeutics (NTLA) Receives a Sell from Goldman Sachs
Canaccord Genuity Analyst forecast on GB:0JBU
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$49
Buy
274.90%
Upside
Reiterated
08/06/26
Analyst Maintains Buy on Intellia as Lonvo-z Progress and Strong Cash Runway Support Unchanged $49 Price Target
RBC Capital Analyst forecast on GB:0JBU
Luca Issi
RBC Capital
RBC Capital
$15
Hold
14.77%
Upside
Reiterated
08/06/26
RBC Capital Sticks to Its Hold Rating for Intellia Therapeutics (NTLA)
Wolfe Research Analyst forecast on GB:0JBU
Andy Chen
Wolfe Research
Wolfe Research
$9
Sell
-31.14%
Downside
Downgraded
07/15/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (NYSE: BLCO) and Intellia Therapeutics (NASDAQ: NTLA)
J.P. Morgan Analyst forecast on GB:0JBU
Brian Cheng
J.P. Morgan
J.P. Morgan
$8
Sell
-38.79%
Downside
Reiterated
05/13/26
J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AMRXAmneal Pharmaceuticals
DNTHDianthus Therapeutics
REPLReplimune Group
VSTMVerastem
OVIDOvid Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Intellia Therapeutics

3 Months
Mani ForooharLeerink Partners
Success Rate
14/39 ratings generated profit
36%
Average Return
+4.67%
Copying Mani Foroohar's trades and holding each position for 3 Months would result in 35.90% of your transactions generating a profit, with an average return of +4.67% per trade.
1 Year
Joon LeeUBS
Success Rate
7/22 ratings generated profit
32%
Average Return
-2.99%
Copying Joon Lee's trades and holding each position for 1 Year would result in 31.82% of your transactions generating a profit, with an average return of -2.99% per trade.
2 Years
Joon LeeUBS
Success Rate
5/22 ratings generated profit
23%
Average Return
-31.75%
Copying Joon Lee's trades and holding each position for 2 Years would result in 22.73% of your transactions generating a profit, with an average return of -31.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0JBU Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
10
5
6
5
5
Buy
5
4
3
2
2
Hold
13
10
7
5
6
Sell
4
4
3
2
2
Strong Sell
0
0
0
0
0
total
32
23
19
14
15
In the current month, 0JBU has received 7 Buy Ratings, 6 Hold Ratings, and 2 Sell Ratings. 0JBU average Analyst price target in the past 3 months is 19.91.
Each month's total comprises the sum of three months' worth of ratings.

0JBU Financial Forecast

0JBU Earnings Forecast

Next quarter’s earnings estimate for 0JBU is -$0.80 with a range of -$0.89 to -$0.72. The previous quarter’s EPS was -$0.80. 0JBU beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0JBU has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0JBU is -$0.80 with a range of -$0.89 to -$0.72. The previous quarter’s EPS was -$0.80. 0JBU beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0JBU has Performed in-line its overall industry.

0JBU Sales Forecast

Next quarter’s sales forecast for 0JBU is $9.74M with a range of $0.00 to $15.00M. The previous quarter’s sales results were $7.66M. 0JBU beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0JBU has Performed in-line its overall industry.
Next quarter’s sales forecast for 0JBU is $9.74M with a range of $0.00 to $15.00M. The previous quarter’s sales results were $7.66M. 0JBU beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0JBU has Performed in-line its overall industry.

0JBU Stock Forecast FAQ

What is GB:0JBU’s average 12-month price target, according to analysts?
Based on analyst ratings, Intellia Therapeutics’s 12-month average price target is 19.91.
    What is GB:0JBU’s upside potential, based on the analysts’ average price target?
    Intellia Therapeutics has 52.33% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Intellia Therapeutics a Buy, Sell or Hold?
          Intellia Therapeutics has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 5 hold ratings and 2 sell ratings.
            What is Intellia Therapeutics’s share price target?
            The average share price target for Intellia Therapeutics is 19.91. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $49.00 ,and the lowest forecast is $8.00. The average share price target represents 52.33% Increase from the current price of $13.07.
              What do analysts say about Intellia Therapeutics?
              Intellia Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of Intellia Therapeutics?
                To buy shares of GB:0JBU, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.